Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Telisotuzumab vedotin by AbbVie for Non-Small Cell Lung Cancer: Likelihood of Approval
Telisotuzumab vedotin is under clinical development by AbbVie and currently in Phase III for Non-Small Cell Lung Cancer. According to...
Data Insights
Telisotuzumab vedotin by AbbVie for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval
Telisotuzumab vedotin is under clinical development by AbbVie and currently in Phase II for Squamous Non-Small Cell Lung Cancer. According...